NCT02842866View on ClinicalTrials.gov

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

PHASE3CompletedINTERVENTIONAL
Enrollment

907

Participants

Timeline

Start Date

July 15, 2016

Primary Completion Date

February 13, 2017

Study Completion Date

February 13, 2017

Conditions
MeningitisMeningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine

0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.

BIOLOGICAL

Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined

0.5 mL, Subcutaneous (SC), single dose on Day 0.

Trial Locations (36)

13760

Endwell

15401

Uniontown

18012

Allentown

21075

Elkridge

22911

Charlottesville

27103

Winston-Salem

27408

Greensboro

27612

Raleigh

29464

Mt. Pleasant

29646

Mt. Pleasant

32081

Ponte Vedra

32127

Port Orange

32205

Jacksonville

32216

Jacksonville

32720

DeLand

33409

West Palm Beach

33756

Clearwater

45236

Cincinnati

45246

Cincinnati

48098

Troy

58104

Fargo

63141

St Louis

66219

Lenexa

67114

Newton

67205

Wichita

75231

Dallas

75234

Dallas

84088

West Jordan

84095

South Jordan

85224

Chandler

92103

San Diego

92801

Anaheim

97527

Grants Pass

06708

Waterbury

02169

Quincy

00918

San Juan

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02842866 - Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older | Biotech Hunter | Biotech Hunter